Diabetic Foot Ulcer
Conditions
Brief summary
The purpose of this study is to determine whether dehydrated human amnion/chorion membrane (dHACM) is more effective than another commercially available product or conservative measures alone when used to treat diabetic foot ulcers (DFUs).
Detailed description
This is a prospective, stratified, randomized, controlled, comparative, parallel group, multi-center clinical trial comparing the proportion of ulcers completely healed by use of dehydrated human amnion/chorion membrane (dHACM) placed weekly versus placement of bioengineered skin substitute (BSS) placed weekly, versus standard of care in diabetic patients with a diabetic foot ulcer who have adequate arterial perfusion as defined in section, 2.0 (Patient Eligibility), for wound healing to the affected limb.
Interventions
PROCEDUREDressing Application
Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
DEVICEOffloading
Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading.
Sponsors
MiMedx Group, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients age 18 or older. 2. Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study. 3. Patient's ulcer must be diabetic in origin and larger than 1 cm2. Note: Debridement will be done prior to randomization. Subject's informed consent for participating in this study, must be obtained prior to proceeding with sharp debridement. 4. Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA). 5. Ulcer must be present for a minimum of four weeks before enrollment/ randomization, with documented failure of conventional ulcer therapy to heal the wound. A two week run-in period will precede enrollment/ randomization in the trial to document the indolent nature of the wounds selected. 6. Additional wounds may be present but not within 3 cm of the study wound. 7. Wound must be present anatomically on the foot as defined by beginning below the malleoli of the ankle and be neuropathic in origin. 8. Patient's ulcer must exhibit no clinical signs of infection. 9. Serum Creatinine less than 3.0mg/dl within last six months. 10. HbA1c less than or equal to 12% within last 90 days. 11. Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days: 1. Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg, OR 2. ABIs with results of ≥0.7 and ≤1.2, OR 3. Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg.
Exclusion criteria
1. Patients presenting with an ulcer probing to tendon, muscle, capsule or bone (UT Grade IIIA-D). A positive probe-to-bone will be confirmed when bone or joint can be felt with a sterile, ophthalmological probe. 2. Patients whose index diabetic foot ulcers are greater than 25 cm2. 3. Patients considered not in reasonable metabolic control, confirmed by an HbA1c greater than 12% within previous 90 days. 4. Patients whose serum creatinine levels are 3.0mg/dl or greater within the last six months. 5. Patients with a known history of poor compliance with medical treatments. 6. Patients who have been previously randomized into this study, or are presently participating in another clinical trial. 7. Patients who are currently receiving radiation therapy or chemotherapy. 8. Patients with known or suspected local skin malignancy to the index diabetic ulcer. 9. Patients diagnosed with autoimmune connective tissues diseases. 10. Non-revascularizable surgical sites. 11. Active infection at site. 12. Any pathology that would limit the blood supply and compromise healing. 13. Patients that have received a biomedical or topical growth factor for their wound within the previous 30 days. 14. Patients who are pregnant or breast feeding. 15. Patients who are taking medications that are considered immune system modulators which could affect graft incorporation. 16. Known allergy to Gentamicin or Streptomycin, or to bovine collagen. 17. Patients with known hypersensitivity to components of any treatment used in the trial. 18. Wounds greater than one year in duration without intermittent healing. 19. Wounds improving greater than 20% over the first two weeks (run-in period) of the trial using standard of care dressing and camboot. 20. Patients taking Cox-2 inhibitors. 21. Planned use of Dakin's solution, Mafenide Acetate, Scarlet Red Dressing, Tincoban, Zinc Sulfate, Povidone Iodine solution, Mafenide Acetate, Polymyxin/Nystatin or Chlorhexidine during trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of ulcers achieving 100% epithelialization in the dHACM group vs other commercially available product and control. | 6 weeks | Visitrak Wound Measurement System |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients achieving 100% epithelialization in dHACM group vs other commercially available product and control. | 12 weeks | Visitrak Wound Measurement System |
| Cost effectiveness of each treatment modality. | 12 weeks | Cost of product x number of visits |
Countries
United States
Outcome results
None listed